imatinib mesylate has been researched along with Experimental Neoplasms in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Biagioni, S; Brancaccio, D; Bufano, M; Ceramella, J; Coluccia, A; Coluccia, AML; Da Pozzo, E; Hamel, E; Iacopetta, D; La Regina, G; Liu, T; Martini, C; Nalli, M; Orlando, V; Puxeddu, M; Sebastiani, J; Shen, H; Silvestri, R; Sinicropi, MS; Tremolanti, C | 1 |
| Fang, L; Huang, B; Li, J; Li, SQ; Liao, ZH; Lin, J; Liu, J; Min, QH; Wang, XZ; Wang, Y; Wu, Y; Xu, YM; Yang, WM; Zhang, HB; Zhang, J | 1 |
| Armstrong, AE; Bessler, W; Blakeley, JO; Chen, S; Clapp, DW; Ferguson, MJ; Ingram, DA; Jiang, L; Li, X; Rhodes, SD; Robertson, KA; Smith, A; Yang, FC; Yang, X; Yuan, J | 1 |
| Azam, M; Bouso, MF; Cancelas, JA; Gomaa, A; Grimes, HL; Huber, E; Kesarwani, M; Kincaid, Z; Komurov, K; Latif, T; Mulloy, JC; Rohrabaugh, S; Siddiqui, Z; Xu, M | 1 |
| Al-Tamimi, J; Alhazza, IM; Aman, S; Ebaid, H; Hassan, I; Khan, AA; Qamar, W; Rady, AM | 1 |
| Ghanghas, P; Kumar, K; Sanyal, SN | 1 |
| Jaggi, M; Negi, LM; Talegaonkar, S; Verma, AK | 1 |
| Doki, N; Harada, H; Harada, Y; Inoue, D; Izawa, K; Kakihana, K; Katayama, Y; Kawabata, KC; Kitamura, T; Kitaura, J; Maehara, A; Matsui, T; Nakahara, F; Nishimura, K; Ohashi, K; Oki, T; Sada, A; Togami, K; Uchida, T; Yoshioka, K | 1 |
| Gai, Y; Lu, M; Lu, Y; Ma, X; Xiang, G; Yang, T; Ye, P; Zhang, W | 1 |
| Baldini, C; Bridal, SL; Comperat, E; Dizeux, A; Lamuraglia, M; Le Guillou-Buffello, D; Lucidarme, O; Payen, T | 1 |
| Arts, FA; Chand, D; Constantinescu, S; Demoulin, JB; Hallberg, B; Pecquet, C; Velghe, AI | 1 |
| Ohyashiki, K; Okabe, S; Sakuta, J; Tanaka, Y; Tauchi, T | 1 |
| Åhgren, A; Burmakin, M; Heldin, CH; Hellberg, C; Olsson, PO; Reed, RK; Rubin, K; Stuhr, L; van Wieringen, T | 1 |
| Duskova, M; Petrackova, M; Sobotkova, E; Tachezy, R; Vonka, V | 1 |
| Jin, Y; Lai, Y; Lu, Z; Pan, J; Qiu, L | 1 |
| Ashihara, E; Kimura, S; Lyons, JF; Maekawa, T; Nagao, R; Ottmann, OG; Reule, M; Smyth, T; Squires, MS; Takeuchi, M; Tanaka, R; Thompson, NT; Yamauchi, T; Yao, H; Yokota, A | 1 |
| Chayama, K; Kitadai, Y; Kodama, M; Ohara, E; Ohnishi, M; Shinagawa, K; Sumida, T; Tanaka, M; Tanaka, S; Yasui, W | 1 |
| Fan, D; Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Logothetis, C; Mathew, P; Shepherd, DL; Tsan, R; Uehara, H | 1 |
| Huelsmeyer, MK; Katayama, R; Kurzman, ID; Marr, AK; Thamm, DH; Vail, DM | 1 |
| Abe, M; Baranowska-Kortylewicz, J; Enke, CA; Nearman, J | 1 |
| Bartholomeusz, GA; Donato, NJ; Estrov, Z; Kapuria, V; Kong, LY; Priebe, W; Talpaz, M; Wang, S; Wu, J | 1 |
| Bonmort, M; Chaput, N; Kroemer, G; Ménard, C; Mignot, G; Taieb, J; Tursz, T; Ullrich, E; Viaud, S; Zitvogel, L | 1 |
| Andrade-Gordon, P; Friedlander, M; Kurokawa, T; Mueller, BM; Ruf, W; Uusitalo-Jarvinen, H | 1 |
| Sawyers, CL | 1 |
| Demetri, GD | 1 |
| Bankson, JA; Bornmann, W; Chen, J; Crespo, A; Fernández, A; Gelovani, J; Han, HD; Lin, Y; Lopez-Berestein, G; Ma, J; Mangala, LS; Ozturk, E; Peng, Z; Qin, C; Samarel, A; Sanguino, A; Shavrin, A; Sood, AK; Trent, J; Wulf, S | 1 |
| Apetoh, L; Bonmort, M; Bosisio, D; Bulfone-Paus, S; Chaput, N; Ferrantini, M; Mack, M; Ménard, C; Mignot, G; Ryffel, B; Schmitz, J; Sozzani, S; Taieb, J; Ullrich, E; Zitvogel, L | 1 |
| Cleris, L; Formelli, F; Greco, A; Miranda, C; Pierotti, MA; Roccato, E | 1 |
1 review(s) available for imatinib mesylate and Experimental Neoplasms
| Article | Year |
|---|---|
Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Dendritic Cells; Imatinib Mesylate; Immunotherapy; Interferon-gamma; Mice; Neoplasms, Experimental; Piperazines; Pyrimidines | 2007 |
1 trial(s) available for imatinib mesylate and Experimental Neoplasms
| Article | Year |
|---|---|
Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Benzamides; Blast Crisis; Female; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; mRNA Cleavage and Polyadenylation Factors; Mutation, Missense; Neoplasms, Experimental; Oncogene Proteins, Fusion; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Transcription Factor HES-1 | 2014 |
26 other study(ies) available for imatinib mesylate and Experimental Neoplasms
| Article | Year |
|---|---|
Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Glioblastoma; Heterocyclic Compounds; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methane; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Polymerization; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2021 |
Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
Topics: Animals; bcl-X Protein; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholinos; Neoplasms, Experimental; RNA Splicing; Xenograft Model Antitumor Assays | 2020 |
Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
Topics: Animals; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Mice; Mice, Transgenic; Neoplasms, Experimental; Neurofibroma, Plexiform; Neurofibromatosis 1 | 2020 |
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Topics: Adult; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Female; Flow Cytometry; Gene Expression Profiling; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Knockout; Mice, Transgenic; Middle Aged; Neoplasm Transplantation; Neoplasm, Residual; Neoplasms, Experimental; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Real-Time Polymerase Chain Reaction; Tumor Stem Cell Assay | 2017 |
Restrained management of copper level enhances the antineoplastic activity of imatinib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemotherapy, Adjuvant; Copper; Disulfiram; Drug Synergism; Imatinib Mesylate; Metabolism; Neoplasms, Experimental; Rats; Treatment Outcome | 2018 |
Chemopreventive action of Imatinib, a tyrosine kinase inhibitor in the regulation of angiogenesis and apoptosis in rat model of lung cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; Female; Imatinib Mesylate; Inflammation; Lipopolysaccharides; Lung Neoplasms; Neoplasm Proteins; Neoplasms, Experimental; Neovascularization, Pathologic; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley | 2018 |
Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Hyaluronic Acid; Imatinib Mesylate; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms, Experimental | 2019 |
Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting.
Topics: Antineoplastic Agents; Benzamides; Cell Survival; Combined Modality Therapy; Diffusion; Drug Synergism; Folate Receptors, GPI-Anchored; Folic Acid; HeLa Cells; Humans; Imatinib Mesylate; Liposomes; Molecular Targeted Therapy; Neoplasms, Experimental; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Monitoring; Female; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Molecular Imaging; Neoplasms, Experimental; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Female; Growth Disorders; Humans; Imatinib Mesylate; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutagenesis, Site-Directed; Mutation; Myofibromatosis; Neoplasms, Experimental; NIH 3T3 Cells; Oncogenes; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Syndrome | 2016 |
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines | 2016 |
Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Collagen; Colonic Neoplasms; Extracellular Fluid; Extracellular Matrix; Imatinib Mesylate; Mice, SCID; Neoplasms, Experimental; Oxygen; Pressure; Receptor, Platelet-Derived Growth Factor beta; Stromal Cells; Tumor Burden; Water | 2017 |
Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cancer Vaccines; Cell Line, Transformed; Combined Modality Therapy; Cyclophosphamide; Female; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Imatinib Mesylate; Immunotherapy; Interferon-gamma; Interleukin-12; Interleukin-2; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Piperazines; Polymerase Chain Reaction; Pyrimidines | 2009 |
Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; Pentacyclic Triterpenes; Piperazines; Pyrimidines; Signal Transduction; Triterpenes; Xenograft Model Antitumor Assays | 2010 |
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Urea | 2010 |
Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma.
Topics: Aged; Animals; Benzamides; Blotting, Western; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Stromal Cells | 2010 |
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microcirculation; Neoplasms, Experimental; Paclitaxel; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Radiographic Image Enhancement; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Tumor Cells, Cultured | 2003 |
Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cat Diseases; Cats; Imatinib Mesylate; Mice; Mice, Nude; Neoplasms, Experimental; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Vaccines | 2004 |
Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer.
Topics: Animals; Benzamides; Cell Line, Tumor; Female; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Piperazines; Pressure; Pyrimidines; Radioimmunotherapy; Receptor, Platelet-Derived Growth Factor beta; Time Factors | 2007 |
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Topics: Animals; Apoptosis; Benzamides; Blast Crisis; Cell Line, Tumor; Cyanoacrylates; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Tumor Stem Cell Assay | 2007 |
Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis.
Topics: Animals; Benzamides; Blood Coagulation Factor Inhibitors; Cell Line, Tumor; Disease Models, Animal; Factor VIIa; Hyperoxia; Hypoxia; Imatinib Mesylate; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neoplasms, Experimental; Neovascularization, Pathologic; Oxygen; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, PAR-1; Receptor, PAR-2; Retinal Neovascularization; Retinal Vessels; Signal Transduction; Thromboplastin; Time Factors | 2007 |
Where lies the blame for resistance--tumor or host?
Topics: ADP-Ribosylation Factor 1; Animals; Benzamides; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Ligands; Mice; Models, Immunological; Neoplasms, Experimental; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Receptors, Cytokine | 2007 |
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Topics: Animals; Benzamides; Cardiotoxins; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Heart Diseases; Humans; Imatinib Mesylate; K562 Cells; MAP Kinase Kinase 4; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Rats, Sprague-Dawley | 2007 |
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Topics: Animals; Benzamides; Cardiotoxins; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Heart Diseases; Humans; Imatinib Mesylate; K562 Cells; MAP Kinase Kinase 4; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Rats, Sprague-Dawley | 2007 |
The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemokine CCL2; Dendritic Cells; Flow Cytometry; Humans; Imatinib Mesylate; Interferon gamma Receptor; Interleukin-15; Interleukin-2; Killer Cells, Natural; Mice; Mice, Mutant Strains; Neoplasms, Experimental; Piperazines; Pyrimidines; Receptors, CCR2; Receptors, Interferon | 2008 |
Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Dermatofibrosarcoma; Disease Models, Animal; Gene Rearrangement; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2001 |